Stocks Pfizer Inc

  • Markets opened mixed on Thursday. What should investors expect from stocks going forward? Ray Harrison, founder of Harrison Financial Group, and Bill Smead, CEO and CIO of Smead Capital Management, shared their investment plays.

  • Traders are coming to the realization that corporate America presented their most exciting earnings reports first in this earnings season.

  • If your investment strategy is ‘slow and steady wins the race,’ Pete Najarian has a trade for you.

  • Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • merck_entrance_200.jpg

    These have been sunny days for Merck. Setting aside today’s action, the stock’s been on a pretty good tear lately hitting levels not seen in nearly two years. But the sun isn’t shining everywhere within the company.

  • Following are the day’s biggest winners and losers. Find out why shares of Pfizer and El Paso popped while Sprint and Imax dropped.

  • Wall Street is closely watching the outcome of the special election in Massachusetts. It could have a big impact on the entire landscape in DC.

  • On Tuesday, the Fast Money traders were poring over results from IBM after big blue beat expectations but then sold-off in the after-market.

  • With a slew of banks set to report earnings this week, the Fast Money desk is closely watching the action in the financials. Is weakness already priced in?

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks edged lower at the open Friday, with investors unimpressed over earnings beats from Intel and JPMorgan Chase as well as economic readings in line with expectations.

  • Were you so preoccupied with tech on Thursday that you missed the important action in Pharma. If so, Pete Najarian has got you covered!

  • Sure you like his show, but what about his book? Peak inside the playbook of celebrity talk show titan, Regis Philbin.

  • Vivus is getting the JPMorgan Healthcare Conference off to a sexy start. The company announced this morning that its late-stage experimental erectile dysfunction drug apparently gets the job done in 15 minutes.

  • The traders are closely watching potential hot stocks ahead of the JPMorgan Health Care conference next week.

  • Jeff Kindler, Pfizer Chairman and CEO

    No one in their right mind, especially in this economy, likes to see someone lose their job. (Well, unless you really can't stand the person.) But, on the other hand, when you hear the top exec of the world's biggest drug company talk candidly about how much fat there was (is?) at Pfizer, can you really blame him for swinging the ax?

  • Bonds and certificates of deposit have long been considered safer investments than stocks. But in an era of incredibly low interest rates, Cramer said, buying the former two could be a mistake. A CD right now might offer a 1.5% return, while 10-year Treasurys pay you 3.75%. A company with a high-yielding dividend, however, can generate more than 7% (see: Kinder Morgan Energy Partners, among others). But even stocks with sub-4% yields these days may net more than those 10-years because dividends

    Read on for Cramer’s nine newest dividend plays. Just remember: The numbers listed here were correct as of publish time, but they may have changed a bit since. So do your homework!

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks rallied on the first trading day of the new year, buoyed by a trifecta of news: A report that showed growth in the manufacturing sector, the dollar's pullback and an upgrade on Intel.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks looks set to start the last day of 2009 with a slight gain, although volume could be thin with many investors looking to pop the champagne corks early.

  • dogs_ofthe_dow.jpg

    A popular investment strategy suggests buying the ten Dow Jones Industrial Average components with the highest yielding dividends. Here is the list going into 2010.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks looks set to start the last day of 2009 with a slight gain, although volume could be thin with many investors looking to pop the champagne corks early.